Study Analyzes What Happens when Patients Stop Taking GLP-1 Drugs

Study analyzes what happens when patients stop taking GLP-1 drugs

Overall, the analysis showed that stopping the drugs doesn't lead to significant weight regain.

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment. In one of the

What happens when patients stop taking GLP-1 drugs?

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment. In one of the…

New Cleveland Clinic Study Uncovers Real-World Effects of Discontinuing

In recent years, the advent and expanding use of injectable GLP-1 receptor agonists have revolutionized the management of obesity and type 2 diabetes, offering unprecedented efficacy in weight reduction and glycemic control. Among these agents, semaglutide and tirzepatide have emerged as frontrunners, heralded for their potent anorectic and metabolic effects. However, a significant clinical question looms large: what transpires when patients dis…